CLBT Stock Forecast & Price Target

Cellebrite DI is attractive because its core digital investigation platform is still posting strong underlying demand, with ARR reaching $507.8 million, up 21% year over year, while D&I ARR grew 25% year over year and Genesis traction is building toward $1 million of ARR. The company’s newer AI-powered products, including Genesis and C-Tek, appear to be expanding its addressable market and improving long-term monetization, while conversion economics should support margin accretion as free trials turn into paid users and Genesis becomes accretive to gross profit and the P&L. Even after Q2’s miss and guidance reset, management still raised adjusted EBITDA guidance to $153 million to $159 million and the business continues to generate 30%-plus free cash flow margins, reinforcing the view that near-term execution issues do not undermine the durable fundamental growth story.

Cellebrite DI is vulnerable because roughly 90% of revenue comes from public sector customers, including a high-teens percentage from U.S. federal, leaving results exposed to budget delays, shutdowns, procurement friction, and elongated sales cycles. The recent Q2 miss showed this sensitivity: revenue of $131.1 million and EBITDA of $31.8 million were near guidance, but subscription revenue of $119.5 million, ARR of $507.8 million, and especially $6.0 million of free cash flow fell short as large government deals slipped. Beyond demand risk, the business faces structural pressure from fast-moving competitors and smartphone security patches, while the CEO change and lowered CY26 and CY27 guidance signal fading momentum after the Inseyets tailwind.